Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
March 25, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist